DOT1L and acute myeloid leukemia: For DOT1L, it has been reported that both genetic and pharmacological targeting results in delayed (4–10 day) effects on transcriptional regulation and cell viability in AML [41, 45], which can be explained by the slow turnover rate of pre-existing H3K79 methylation [46].